A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

← catalyst calendar

NCT07188558 · readout ≤ 1,229 d

Sponsored by Lyell Immunopharma, Inc. (industry) · LYEL — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

400estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-12

actual

When the study began enrolling

Primary completion

Dec 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2032

estimated

The whole study's end, after follow-up

First posted

2025-09-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Large B-cell Lymphoma
Lymphoma, B-Cell
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma Refractory/ Relapsed
Diffuse Large B Cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma Refractory
Diffuse Large B Cell Lymphoma Relapsed

Interventions

Biological: rondecabtagene autoleucel — also filed as LYL314
Biological: axicabtagene ciloleucel — also filed as Yescarta, axi-cel
Biological: lisocabtagene maraleucel — also filed as Breyanzi, liso-cel

Primary outcome

what the primary-completion date above is the date OF

Event free survival

measured 36 months

Permalink · LYEL's whole pipeline · Catalyst calendar · Every registered study · What changed